Reuters
Published Jun 01, 2022 06:58AM ET
Updated Jun 01, 2022 08:31AM ET
(Reuters) -Sage Therapeutics Inc and Biogen (NASDAQ:BIIB)'s experimental drug improved symptoms of postpartum depression after 15 days in a late-stage study, the companies said on Wednesday.
The drug, zuranolone, also reduced depression severity as early as the third day of treatment compared with placebo in the study conducted among 200 adult women.
Zuranolone, Sage's most advanced drug candidate, is being developed for the treatment of major depressive disorder as well. It improved depression symptoms in two late-stage studies, but there have been concerns about its effectiveness and durability.
Analysts have said the near-term durability of the oral drug would be important for its broader commercial success and expressed concerns about whether its data in MDD would limit market opportunity.
While Wednesday's announcement bodes well for zuranolone, postpartum depression is a smaller market opportunity than major depressive disorder, said Truist Securities analyst Robyn Karnauskas.
The target population for major depressive disorder is higher than postpartum depression, but the latter's "competitive intensity is much lower", Sage Chief Innovation Officer Jeff Jonas told Reuters.
Postpartum depression occurs after having a baby, with symptoms similar to depression and can include excessive worrying, crying and feelings of anger.
About 1 in 8 women experience symptoms of postpartum depression, according to the U.S. Centers of Disease Control and Prevention (CDC).
A previous late-stage study testing a lower dose of zuranolone for postpartum depression had also met the main goal, according to the company.
Sage signed a deal worth up to $1.5 billion with Biogen in 2020 to develop zuranolone along with another experimental drug.
The companies started submitting data on the drug to the U.S. health regulator for the treatment of major depressive disorder earlier this month and expect to complete the marketing application in the second half of the year.
They expect to file for the drug's approval for postpartum depression early next year.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.